Adam Gibb

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Bilateral adrenal masses and adrenal insufficiency: a rare case of primary adrenal lymphoma.

Bilateral adrenal masses and adrenal insufficiency: a rare case of primary adrenal lymphoma.

Journal: Endocrinology, diabetes & metabolism case reports

Published: October 04, 2025

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Journal: Leukemia & lymphoma

Published: June 30, 2025

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

Journal: British journal of haematology

Published: February 06, 2024

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.

Journal: Haematologica

Published: January 08, 2024

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.

Journal: HemaSphere

Published: October 29, 2023

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Journal: Blood advances

Published: July 26, 2023

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Journal: Blood advances

Published: July 14, 2023

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Journal: British journal of haematology

Published: July 08, 2023

CAR T in patients with large B-cell lymphoma not fit for autologous transplant.

CAR T in patients with large B-cell lymphoma not fit for autologous transplant.

Journal: British journal of haematology

Published: January 11, 2023

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Journal: British journal of haematology

Published: February 15, 2021

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

Journal: Blood advances

Published: June 05, 2020

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).

Journal: British journal of haematology

Published: March 06, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026